Raymond James has resumed coverage of Amgen Inc (NASDAQ:AMGN), noting a diversified portfolio where Amgen has a strong presence that can help drive solid, sustainable long-term growth.
Raymond James writes that Amgen has effectively diversified its portfolio across various therapeutic areas, reducing concentration risk and enhancing growth potential.
Recent deals, like the Horizon deal, have bolstered its presence in rare diseases, positioning it for substantial growth. Successful launches of key products have further strengthened its position.
Raymond James resumes with a Market Perform rating.
Recently, Amgen’s data from animal and early-stage human trials of its experimental obesity drug ...